Drugs / 52364
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00547014 | Sep 2007 → Apr 2008 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 52364 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00547014 ↗ |
| Known as | CPG 52364 | “Oral Administration Of CPG 52364 In Healthy Subjects: A Phase 1, Within-Cohort Randomized, Double-Blinded, Placebo-Controlled, Ascending Single-Dose, Single-Center Study” NCT00547014 ↗ |
| Route | Oral | “3 mg capsule single dose administered orally as a single dose” NCT00547014 ↗ |